Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Uwe Pelzer; Ingo Schwaner; Jens Stieler; Mathias Adler; Jörg Seraphin; Bernd Dörken; Hanno Riess; Helmut Oettle

doi:10.1016/j.ejca.2011.04.011

journal article Jul 01, 2011

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

Uwe Pelzer

Ingo Schwaner Jens Stieler Mathias Adler Jörg Seraphin Bernd Dörken Hanno Riess Helmut Oettle

European Journal of Cancer Vol. 47 No. 11 pp. 1676-1681 · Elsevier BV

View at Publisher Save 10.1016/j.ejca.2011.04.011

Topics

No keywords indexed for this article. Browse by subject →

References

19

[1]

Stathis "Advanced pancreatic carcinoma: current treatment and future challenges" Nat Rev Clin Oncol (2010) 10.1038/nrclinonc.2009.236

[2]

Jemal "Cancer statistics" CA Cancer J Clin (2009) 10.3322/caac.20006

[3]

Burris "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial" J Clin Oncol (1997) 10.1200/jco.1997.15.6.2403

[4]

Pelzer "First-line chemotherapy in advanced pancreatic cancer" Recent Results Cancer Res (2008) 10.1007/978-3-540-71279-4_7

[5]

Heinemann "Accomplishments in 2008 in the treatment of metastatic pancreatic cancer" Gastrointest Cancer Res (2009)

[6]

Cunningham "Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer" J Clin Oncol (2009) 10.1200/jco.2009.24.2446

[7]

Pelzer "Second-line chemotherapy in advanced pancreatic cancer" Recent Results Cancer Res (2008) 10.1007/978-3-540-71279-4_8

[8]

Oettle "Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma" Anticancer Drugs (2000) 10.1097/00001813-200009000-00006

[9]

Kulke "Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer" J Clin Oncol (2007) 10.1200/jco.2007.11.8521

[10]

Pelzer "Second-line therapy in refractory pancreatic cancer. Results of a phase ii study" Onkologie (2009) 10.1159/000197769

[11]

Tsavaris "Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study" Invest New Drugs (2005) 10.1007/s10637-005-1446-y

[12]

Ko "Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study" Cancer Invest (2008) 10.1080/07357900701681483

[13]

Cereda "Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer" J Chemother (2008) 10.1179/joc.2008.20.4.509

[14]

Boeck "Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial" Ann Oncol (2007) 10.1093/annonc/mdl463

[15]

Reni "Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer" Br J Cancer (2006) 10.1038/sj.bjc.6603026

[16]

Morizane "A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer" Cancer Chemother Pharmacol (2009) 10.1007/s00280-008-0741-7

[17]

Kindler "Arsenic trioxide in patients with adeno-carcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium" Am J Clin Oncol (2008) 10.1097/coc.0b013e318178e4cd

[18]

Ignatiadis "A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer" Oncology (2006) 10.1159/000106064

[19]

Heinemann "Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer" BMC Cancer (2008) 10.1186/1471-2407-8-82

Cited By

285

Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Angélique Vienot, Guillaume Beinse · 2017

JNCI Journal of the National Cancer...

Second-Line Treatment in Pancreatic Cancer Patients

Marianne Sinn, Louise Dälken · 2016

Pancreas

Metrics

285

Citations

19

References

Details

Published: Jul 01, 2011
Vol/Issue: 47(11)
Pages: 1676-1681
License: View

Authors

From the Max Delbrück Center for Molecular Medicine, Berlin-Buch, Germany; Department of Internal Medicine, Robert-Rössle-Klinik, University Medical Center Charité, Humboldt University of Berlin, Berlin, Germany; and Institute of Immunology, University of Munich, Munich, Germany.

H

Hanno Riess

Internistischen Onkologie/Campus Virchow-Klinikum, Charité-Universitätsmedizin, Berlin, Germany

H

Helmut Oettle

Marianne Sinn, Marcus Bahra, Uwe Pelzer, Jens M. Stieler, Jana K. Striefler, Sven Bischoff, Bernd Dörken, and Hanno Riess, Charité–Universitätsmedizin Berlin; Klaus Gellert, Sana Klinikum Lichtenberg, Berlin; Torsten Liersch and Michael Ghadimi, Universitätsmedizin Göttingen, Göttingen; Helmut Messmann, Klinikum Augsburg, Augsburg; Wolf Bechstein, Universitätsklinikum Frankfurt, Frankfurt; Dirk Waldschmidt, Universitätsklinikum Köln, Köln; Lutz Jacobasch, Clinical Center, Dresden; Martin Wilhelm,...

Cite This Article

Uwe Pelzer, Ingo Schwaner, Jens Stieler, et al. (2011). Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. European Journal of Cancer, 47(11), 1676-1681. https://doi.org/10.1016/j.ejca.2011.04.011

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group

You May Also Like